YAG2.F · Atossa Therapeutics, Inc

-

Please sign in to comment on YAG2.F

1 Comment

Admin

4 years ago

Atossa Therapeutics, Inc is currently in a long term uptrend where the price is trading 111.3% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Atossa Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 185.8% to $-7M since the same quarter in the previous year.

Finally, its free cash flow fell by 26.7% to $-3M since the same quarter in the previous year.

Based on the above factors, Atossa Therapeutics, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	US04962H5063
Sector	Healthcare
Industry	Biotechnology

Beta	1.47
Market Cap	74M
PE Ratio	None
Target Price	7.75
Dividend Yield	None

ABOUT

Atossa Therapeutics, Inc

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

YAG2.F · Atossa Therapeutics, Inc

-

Atossa Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Atossa Therapeutics, Inc using a moving average strategy